ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer

[1] Williams SF(1992)High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report J Clin Oncol 10 1743-1747

[2] Gilewski T(1988)High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 16 1368-1376

[3] Mick R(1991)High-dose chemotherapy with reinfusion of purged autologous bone marrow following doseintense induction as initial therapy for metastatic breast cancer J Natl Cancer Inst 83 920-926

[4] Bitran JD(1994)High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoeitic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer Bone Marrow Transplant 13 619-624

[5] Peters WP(1994)Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support Cancer 73 2157-2167

[6] Kennedy MJ(1997)Treatment related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers Bone Marrow Transplant 19 671-678

[7] Vaughan WP(1989)Carboplatin: a preliminary review of its pharmacodynamic and pharmokinetic properties and therapeutic efficacy in the treatment of cancer Drugs 327 162-190

[8] Reed EC(1992)Cisplatin-Cyclophosphamide versus Carboplatin-Cyclophosphamide in advanced ovarian cancer: a randomized Phase III study of the National Cancer Institute of Canada clinical trials group J Clin Oncol 10 718-726

[9] Edwards B(1992)Improved therapeutic index of Carboplatin plus Cyclophosphamide versus Cisplatin plus Cyclophosphamide: Final report by the Soutwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer J Clin Oncol 10 706-717

[10] Kessinger A(1989)Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses J Clin Oncol 7 173-178

[1] Williams SF(1992)High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report J Clin Oncol 10 1743-1747

[2] Gilewski T(1988)High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 16 1368-1376

[3] Mick R(1991)High-dose chemotherapy with reinfusion of purged autologous bone marrow following doseintense induction as initial therapy for metastatic breast cancer J Natl Cancer Inst 83 920-926

[4] Bitran JD(1994)High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoeitic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer Bone Marrow Transplant 13 619-624

[5] Peters WP(1994)Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support Cancer 73 2157-2167

[6] Kennedy MJ(1997)Treatment related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers Bone Marrow Transplant 19 671-678

[7] Vaughan WP(1989)Carboplatin: a preliminary review of its pharmacodynamic and pharmokinetic properties and therapeutic efficacy in the treatment of cancer Drugs 327 162-190

[8] Reed EC(1992)Cisplatin-Cyclophosphamide versus Carboplatin-Cyclophosphamide in advanced ovarian cancer: a randomized Phase III study of the National Cancer Institute of Canada clinical trials group J Clin Oncol 10 718-726

[9] Edwards B(1992)Improved therapeutic index of Carboplatin plus Cyclophosphamide versus Cisplatin plus Cyclophosphamide: Final report by the Soutwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer J Clin Oncol 10 706-717

[10] Kessinger A(1989)Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses J Clin Oncol 7 173-178